about
Immunotherapeutic organoids: a new approach to cancer treatmentGene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.Immune Regulation by Pericytes: Modulating Innate and Adaptive ImmunityIntramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domainsBalanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.The heterotrimeric laminin coiled-coil domain exerts anti-adhesive effects and induces a pro-invasive phenotypeProteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.Basement membrane-rich organoids with functional human blood vessels are permissive niches for human breast cancer metastasis.Selection strategies for anticancer antibody discovery: searching off the beaten path.EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination.The therapeutic potential of engineered human neovessels for cell-based gene therapy.Non-hematopoietic stem cells as factories for in vivo therapeutic protein production.The coming of age of engineered multivalent antibodies.Engineered human tumor xenografts with functional human vascular networks.Role of nucleotide-binding oligomerization domain 1 (NOD1) in pericyte-mediated vascular inflammation.Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytesImproved stability of multivalent antibodies containing the human collagen XV trimerization domain.Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris.Generation and characterization of monospecific and bispecific hexavalent trimerbodies.Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies.In vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement.Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications.Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system.ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.The axonal repellent Slit2 inhibits pericyte migration: potential implications in angiogenesis.A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicityMicroencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer managementEngineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins
P50
Q26853431-D556B774-BA9A-420C-921B-526D7D61D4B7Q27852191-7EF31075-5275-44B5-86CD-649439032267Q28072147-3116CF0F-3B9D-464D-8B71-CD0D29F470F7Q28597266-4BEF48C1-D5C3-4A9A-B460-CA365D5AB604Q33600768-53DB7D03-76AC-44C1-B134-18CDD6C8F3BDQ34314165-FEFC2D25-D233-4284-A80B-E1B26E593769Q34897576-547875CA-E5E4-4866-8CA0-82FEE1A1D422Q34951833-4D22E700-8665-43F9-A767-C8FF56BB37D5Q35589427-007D6090-B202-4425-8302-56737253ECF1Q36490260-1357AA08-48BC-427E-9154-AB4F446D30D3Q37809876-30240350-1FF8-46AE-8DBC-88CD7008D131Q37874445-67A2CBBD-C0BD-4691-BC0C-E216D99B3436Q38372298-9D745FC9-AFBD-4517-B521-0885C5356661Q39646231-56C9D6AA-A412-4FDC-BCFD-1D7F692F69A8Q40162215-F8B73D9F-B04B-407F-8DB7-C7321F6A3B86Q41889316-92930C40-E453-407F-86ED-7102453B384DQ41896363-3B8ADBD3-1315-4893-9569-3FF10D0A0540Q41896587-019688C5-733F-417C-BBE3-049887A76B8AQ42000959-882F55D7-D398-4907-A14A-2FC1C605CD7FQ42413225-C4664D77-80E9-471C-8D7A-EFD62595689DQ42560301-152901DB-96DC-4910-A204-69833650235DQ42729764-666C4692-B458-4753-AF25-7DD44F07F047Q45857985-30B4654E-2583-420A-A93E-E7E6241F1FF4Q47138591-DE5A7212-31A7-4AD1-85BF-2FC4F2BB9CFCQ48750095-362F19A1-A67C-4011-9E15-8AD4EF59F67AQ59136671-A23F194D-1E5A-4650-938B-9FAA9ADB3750Q61622611-03DA5629-EB6F-463F-BEDA-FC99A1841050Q61622721-20AA70C2-4466-470E-B8CC-250ED9383CA7
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Laura Sanz
@ast
Laura Sanz
@en
Laura Sanz
@es
Laura Sanz
@nl
Laura Sanz
@sl
type
label
Laura Sanz
@ast
Laura Sanz
@en
Laura Sanz
@es
Laura Sanz
@nl
Laura Sanz
@sl
prefLabel
Laura Sanz
@ast
Laura Sanz
@en
Laura Sanz
@es
Laura Sanz
@nl
Laura Sanz
@sl
P1053
F-8542-2010
P106
P21
P31
P3829
P496
0000-0002-3119-3218